Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Trial Profile

Phase II European trial of DPX-Survivac (EMD 640744) + temozolomide in patients with maximally resected newly-diagnosed glioblastoma

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jan 2014

At a glance

  • Drugs EMD 640744 (Primary) ; Dendritic cell vaccines; Temozolomide
  • Indications Glioblastoma
  • Focus Pharmacodynamics
  • Most Recent Events

    • 20 Jan 2014 This trial is expected to start in the first half of 2014, according to a Immunovaccine media release.
    • 04 Jun 2013 New trial record
    • 30 May 2013 This trial is expected to start in quarter 4 of 2013, to recruit at least 50 patients, and to provide initial data during the second half of 2014, according to an Immunovaccine Inc media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top